Fig. 1: Outcome and response to belumosudil. | Bone Marrow Transplantation

Fig. 1: Outcome and response to belumosudil.

From: Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy

Fig. 1: Outcome and response to belumosudil.

a Overall survival from belumosudil onset (OS). b Failure-free survival (FFS) for the entire cohort (n = 68) with a median follow-up of 337 days. c FFS for patients receiving belumosudil as a third-line therapy (yellow) or after 3 lines of treatment (blue). Statistical analyses were performed at one year using a log-rank test and a significance defined for p < 0.05. d Stacked histogram with response to belumosudil at 3 months, 6 months and best response during follow-up. e Sankey diagram depicting the evolution of cGVHD grading according to NIH criteria, at GVHD onset, belumosudil onset, 3 months and 6 months. f Sankey diagram illustrating the evolution of response at 3 and 6 months, according to initial cGVHD grading at diagnosis and belumosudil onset. g Stacked diagram with best response per organ.

Back to article page